Improving Outcomes in Diabetes: Focus on SGLT2 Inhibitors. A Medical Experts Discussion
Published: 01 April 2021
This programme has been created with a view to educate primary care healthcare professionals in the UK to understand when, and for whom, they should prescribe SGLT2 inhibitors and to understand the latest advancements in this drug class.
Boehringer Ingelheim Ltd has supported this event as a Medical Education Grant and has had no other involvement in the organisation or the delivery of this programme.
Key Learning Objectives
- Describe how and when to prescribe SGLT2 inhibitors
- Identify patients who are suitable for SGLT2 inhibitors
- Provide appropriate patient education and advice when initiating SGLT2 inhibitors
- Recall the patient populations in whom SGLT2 inhibitors have proven efficacy and safety
- Dr Jas Gill - GP with Special Interest in Cardiology
- Dr Andrew Frankel - Consultant Nephrologist
- Dr Derek Connolly - Consultant Interventional Cardiologist
- Su Down - Nurse Consultant in Diabetes
More from this programme
Welcome and Introductions
Nurse Consultant Diabetes
Su Down is a Nurse Consultant in Diabetes and is the Clinical Lead for the Intermediate Diabetes community service in Somerset. Her Diabetes nursing career started in 1989, when she set up the diabetes specialist nursing service in Yeovil District Hospital. Su took up the role of Nurse Consultant in 2005 and played a key part in redesigning the diabetes service across the whole of Somerset. She continues to work tirelessly to evolve and improve this service to cope with the growing demands of the health care economy.
Nationally she is the Editor in Chief of the Journal of Diabetes Nursing and joint Vice Chair of the PCDS (Primary Care Diabetes Society). Former national roles have included being a TREND associate, board member of FIT (Forum for Injection Technique) and committee member of the Health Care Professionals Council of Diabetes UK.